Home › Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
 

Keywords :   


Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

2015-06-01 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination collaboration announce investigating

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »